Entera Bio Ltd. - ENTX Company profit before taxes, interest and amortization
The success of Entera Bio Ltd. (ENTX) relies on the confirmed efficacy of oral protein administration and patent purity. This EBITDA chart on GURU.Markets shows a turning point driven by the licensing of technologies to pharma behemoths for passive income and the adaptation of the business to regional instability in Israel. Meanwhile, the 0.00 mark serves as a key metric for the company's current operating profit.
Entera Bio (ENTX) - metric breakdowns and financial figures
- market value and analyst target forecast:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Entera Bio Ltd.|ENTX - Long-Term Debt to Capital|Current Liabilities to Capital Entera Bio Ltd|ENTX - Company Debts|Debt to Book Value Ratio Entera Bio|ENTX - Company Long-Term Liabilities|Amount of Current Liabilities Entera Bio|Immediate Liquidity enterabio.com
- earnings and market ratios statistics:
ENTX - Company Net Income|Expected Net Income Entera Bio Ltd.|ENTX - P/E Multiple|Forward P/E Multiple Entera Bio Ltd|ENTX - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Entera Bio|ENTX - Operating profit EBITDA|Earnings per share for the last twelve months Entera Bio|ENTX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months enterabio.com|ENTX - Earnings per share growth in current year|Expected net earnings per share growth next year Entera Bio Ltd.
Analysis of all company metrics:Entera Bio Ltd. - ENTX
To objectively assess the operational efficiency of Entera Bio Ltd. (ENTX), investors must track the actual cash flow from core operations before accounting for debt obligations and taxes. By analyzing the EBITDA metric, one can determine the company's ability to monetize its oral hormone delivery technologies, where growth in this metric would confirm a successful transition from research and development to the commercial sale of drugs.
Competitor analysis for Entera Bio Ltd.
Haleon Corp (HLN) - Profit before interest, taxes and amortization|KVUE: Operating profit before deduction of amortization|veronapharma.com - Company profit before taxes, interest and amortization|MENS: Operating profit EBITDA|Ligand Pharmaceuticals Incorporated - Income before deduction of interest, taxes and amortization|AMRX (Amneal Pharmaceuticals Inc) - Operating profit EBITDA|Profit before interest, taxes and amortization Perrigo Corp PRGO|Profit before payment of interest, taxes and amortization Alvotech (ALVO)|LQDA (liquidia.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA GLPG (Galapagos)|ANI Pharmaceuticals Inc (ANIP) - Profit before interest, taxes and amortization|MNKD - Profit before payment of interest, taxes and amortization|AMPH (Amphastar Corp) - Operating profit before amortization|PCRX (Pacira BioSciences) - Operating profit before deduction of amortization|SPRY: Company profit before taxes, interest and amortization|TBPH (Theravance Biopharma, Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization Aquestive Therapeutics Inc AQST|Profit before payment of interest, taxes and amortization scPharmaceuticals Inc. (SCPH)|TECX (tectonictx.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA TNXP (Tonix Pharmaceuticals)|Operating profit EBITDA SXT Pharmaceuticals SXTC|EPRX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization BHST (BioHarvest Sciences, Inc.)|EXOZ: Operating profit EBITDA|ORMP (Oramed Pharmaceuticals Inc.) - Profit before payment of interest, taxes and amortization|HYFT (MindWalk Holdings) - Operating profit EBITDA|abvcpharma.com (ABVC) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Cumberland Pharmaceuticals Inc. (CPIX)|QNTM - Profit before interest, taxes and amortization|FibroGen Corp - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization TELO|RANI - Profit before payment of interest, taxes and amortization|SNYR: Profit before payment of interest, taxes and amortization|RLYB (rallybio.com) - Operating profit before deduction of amortization|LEXX: Company profit before taxes, interest and amortization|PULM (Pulmatrix Corp) - Operating profit EBITDA|Operating profit before amortization PTHL (Pheton)|Operating profit before deduction of amortization APM (Aptorum Group Limited)|Operating income before deduction of amortization lyratherapeutics.com|Operating profit EBITDA IBO (Impact BioMedical)|TNF Pharmaceuticals Inc. (TNFA) - Profit before interest, taxes and amortization|YCBD - Profit before payment of interest, taxes and amortization|PRFX (PainReform Corp) - Operating profit before amortization|CYTO (altamiratherapeutics.com) - Operating profit before deduction of amortization|LIPO: Company profit before taxes, interest and amortization|Operating profit before deduction of amortization OPTN|Operating profit before amortization PIRS (Pieris Pharmaceuticals Inc)|Profit before payment of interest, taxes and amortization Procaps Group SA (PROC)|PTPI: Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA QLI (Qilian International)|Income before deduction of interest, taxes and amortization SLRN|TFF Pharmaceuticals, Inc. - Operating profit EBITDA
